EN|Investor Relations
The Board

Investor Relations

  • Corporate Governance
  • Announcements
  • Financial Reports
  • Company Presentations
  • Stock Price
  • Analyst Coverage
  • Investor Relations Contacts

The Board

Han Yuewei - Chairman and Non-executive Director


Mr. Han Yuewei, currently serves as a Vice General Manager of China Resources (Holdings) Company Limited (华润(集团)有限公司)(“CR Holdings”). Mr. Han was appointed as an executive Director and chief executive officer, chairman of the Executive Committee, member of the Corporate Governance committee and authorized representative of the Company in October 2019 and was appointed as the chairman of the board and the chairman of the nomination committee of the Company in December 2021. Mr. Han ceased to be the chief executive officer, the chairman of the executive committee, a member of the corporate governance committee and an authorized representative of the Company and was re-designated as a non-executive director and continued to serve as the chairman of the board and the chairman of the nomination committee in January 2022. Mr. Han served as a director of China Resources Sanjiu Medical & Pharmaceutical Company Limited (华润三九医药股份有限公司)(“CR Sanjiu”) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000999) from December 2019 to February 2022, a director of China Resources Double-Crane Pharmaceutical Company Limited (华润双鹤药业股份有限公司)(“CR Double-Crane”) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600062) from December 2019 to February 2022, the chairman and a director of Dong-E-E-Jiao Company Limited (东阿阿胶股份有限公司)(“Dong-E-E-Jiao”) (the shares of which are listed on the Shenzhen Stock Exchange, stock code: 000423) from December 2019 to January 2022 and an executive director of China Resources Medical Holdings Company Limited (“CR Medical”) (the shares of which are listed on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), stock code: 1515) from October 2017 to October 2019, during which he served as the chief executive officer of CR Medical and the general manager of China Resources Healthcare Group Limited, the controlling shareholder of CR Medical. Mr. Han worked for China Resources Land Limited (“CR Land”) (the shares of which are listed on the Stock Exchange , stock code: 1109) from October 2010 to October 2017, during which he served as deputy general manager of Shenyang Region, deputy general manager of Shenzhen Region, director of engineering and vice president of CR Land. Prior to joining CR Land. Han worked as the deputy director and director of the Bureau of Public Works of Shenzhen Municipality (深圳市建筑工务署) from April 2002 to October 2010. Mr. Han obtained a master’s degree in Construction Economics and Management from Tsinghua University (清华大学) and a bachelor’s degree in Construction Management from Tsinghua University in July 1993 and July 1991 respectively.

Bai Xiaosong - Executive Director and Chief Executive Officer


Mr. Bai Xiaosong, was appointed as an executive Director and chief executive officer, the chairman of the Executive Committee, a member of the Corporate Governance Committee and an authorized representative of the Company in January 2022. Mr. Bai currently serves as a director of CR Sanjiu and CR Double-Crane, the chairman and a director of Dong-E-E-Jiao. Mr. Bai served as a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (华润雪花啤酒(中国)有限公司) (“CR Snow Breweries”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (沈阳华润三洋压缩机有限公司), a senior analyst and a sales director of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.

Tao Ran - Executive Director and Vice President


Mr. Tao Ran, was appointed as the vice president of the Company in June 2021 and appointed as an executive Director and a member of the Executive Committee in September 2021. He is concurrently the chairman and director of CR Boya Bio-pharmaceutical, a director of China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (华润江中制药集团有限责任公司) (“ CR Jiangzhong”), a director of CR Zizhu, a director of CR Pharmaceutical Commercial, a chairman of the supervisory board of CR Sanjiu, a chairman of the supervisory board of Dong-E-E-Jiao. Mr. Tao was appointed as a non-executive director of Immunotech in August 2021. Mr. Tao has been a Manager of Division 2, Department of China Nanyang Import and Export Corporation (中国南洋进出口公司) of China Resources National Corporation (currently known as China Resources Company Limited), a senior manager of Investment Division and a deputy general manager of China Resources Textiles (Holdings) Co., Ltd. and a senior director of Strategic Development Division and the general manager of Strategic Development Division of China Resources Pharmaceutical Group Limited. Mr. Tao holds a bachelor’s degree in Engineering awarded by Shanghai Jiao Tong University, and a master’s degree in Economics awarded by Beihang University.

Deng Rong - Executive Director and Chief Financial Officer


Mdm. Deng Rong, was appointed as the chief financial officer of the Company in June 2023, and was appointed as an executive Director and a member of the Executive Committee on 27 December 2023, and she is currently the director of certain subsidiaries of the Company, a director of Jiangzhong Pharmaceutical Co., Ltd. (江中药业股份有限公司) (a subsidiary of the Company listed on the Shanghai Stock Exchange, stock code: 600750.SH), also a director of Dong-E-E-Jiao Co., Ltd. (东阿阿胶) (“Dong-E-E-Jiao”, a subsidiary of the Company, which is 2 listed on the Shenzhen Stock Exchange, Stock Code: 000423.SZ) and a supervisor of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (华润三九) (a subsidiary of the Company, which is listed on the Shenzhen Stock Exchange, Stock Code: 000999.SZ). She previously held various positions within China Resources Double-Crane Pharmaceutical Co., Ltd. (华润双鹤) (“CR Double-Crane”, a subsidiary of the Company, which is listed on the Shanghai Stock Exchange, Stock Code: 600062.SH) from 2004 to 2020, including the Head of Financial Accounting and Tax Management Department at the Financial Management Center, General Manager of the Accounting Management Department at the Financial Management Center, General Manager of the CR Double-Crane Financial Management Center, General Manager of the Financial Shared Services Center, Director of Accounting Management, General Manager of the Business Financial Management Department, and General Manager of the Financial Functional Management Department. She has also served as Vice President, Board Secretary, and Chief Financial Officer at Dong-E-E-Jiao from 2020 to 2023. Mdm. Deng holds a Bachelor's degree

in Accounting from Central South University (中南大学) and a Master's degree in Management from Beijing Jiaotong University (北京交通大学). She is a certified board secretary recognized by the Shenzhen Stock Exchange.

Guo Wei - Non-executive Director


Mdm. Guo Wei, was appointed as a non-executive Director in February 2023, and was appointed as a member of the Audit Committee on 27 December 2023. Mdm. Guo currently serves as a designated external director of the business unit of CR Holdings, Mdm. Guo currently serves as a non-executive director of  China Resources Beer (Holdings) Company Limited, a company listed on the Stock Exchange (stock code: 291). Mdm. Guo was a non-executive Director from May 2019 to September 2021, and was an assistant general manager and a deputy general manager of the Finance Department of CR Holdings from August 2013 to April 2022. Mdm. Guo was a director of CR Double-Crane from December 2015 to September 2021 and a director of CR Sanjiu from April 2018 to September 2021. Mdm. Guo holds a bachelor’s degree in economics from University of International Business and Economics and a master’s degree in law from Peking University.

 

Sun Yongqiang - Non-executive Director


Mr. Sun Yongqiang,was appointed as a non-executive Director and a member of the Remuneration Committee on 27 December 2023. He currently serves as a designated external director of business units of China Resources (Holdings) Company Limited. Mr. Sun joined China Resources Group in March 2001. From 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“CR Land”, which is listed on the Main Board of the Stock Exchange, Stock Code: 1109), and also served as General manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (华润置地(湖南)有限公司, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大连理工大学).

Hou Bo - Non-executive Director


Mr. Hou Bo, was appointed as a non-executive Director in March 2021 and joined the Beijing State-owned Capital Operation and Management Company Limited (“BSCOMC”) in 2019 and is currently an external task director of the BSCOMC. Mr. Hou has many years of experience in financial management. He served as the director of the insurance and non-banking services department of the Beijing Municipal Bureau of Financial Work (京市金融工作局), the director of the financial market department of the Beijing Municipal Bureau of Financial Work (京市金融工作局), the deputy general manager (deputy bureau level) of the former Beijing Equity Exchange Center Co., Ltd. (北京股权交易中心有限公司), and deputy general manager of Zhongguancun Equity Exchange Service Group Co., Ltd. (中关村股权交易服务集团有限公司). Mr. Hou graduated from the Department of Mechanical Engineering of Tsinghua University in 1986 with a bachelor of Engineering degree in Forging and Pressing. He graduated from the Department of Business and Economics of Capital University of Economics and Business with a master degree in Foreign Trade Operations and Management in 1997 and obtained a doctor of Engineering degree in Resources Industry Economics from the school of Earth Sciences and Resources of the China University of Geosciences, Beijing in 2009. He is also a senior international business engineer.


 

Jiao Ruifang - Non-executive Director


Mdm. Jiao Ruifang, was appointed as a non-executive Director and a member of the audit committee of the Company in January 2022. Mdm. Jiao joined the BSCOMC in 2014 and is currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd. (北京城乡商业(集团)股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao was appointed as a director of Hainan Jingliang Holdings Co., Ltd. (海南京粮控股股份有限公司) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000505 and 200505) from March 2022 to September 2022 and Beiqi Foton Motor Co., Ltd. (北汽福田汽车股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) from January 2022 to November 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人 印刷机械股份有限公司), the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited (北京京城机电股份有限公司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (北京天海工业有限公司). Mdm. Jiao holds an MBA in Finance from The Chinese University of Hong Kong-Tsinghua University.

Shing Mo Han Yvonne - Independent Non-executive Director


Mdm. Shing Mo Han Yvonne, BBS, JP, was appointed as an independent non-executive Director and chairman of audit committee, a member of remuneration and appraisal committee, a member of Nomination Committee and a member of Corporate Governance Committee in August 2017. Ms. Shing was appointed as a Justice of Peace of the Hong Kong Special Administrative Region of the People’s Republic of China (the “HKSAR”) in 2013 and awarded the Bronze Bauhinia Star by the HKSAR government in 2017. Ms. Shing was a member of the 10th, 11th and 12th Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference. Ms. Shing’s current appointments include a member of the Board of Governors of EXCEL (Extension and Continuing Education for Life) of The Hong Kong Academy for Performing Arts (“HKAPA”), a court member of the Hong Kong Polytechnic University, an advisor and a member of the Finance Committee of Our Hong Kong Foundation and a member of Hong Kong Deposit Protection Board. Ms. Shing was a partner at Deloitte Touche Tohmatsu/Deloitte China for over 26 years until May 2016. She is currently the chairman of Yinn Advisory Services Limited. Her professional qualifications include fellow member of the Hong Kong Institute of Certified Public Accountants, Association of Chartered Certified Accountants and the Hong Kong Chartered Governance Institute (formerly known as Institute of Chartered Secretaries and Administrators). Ms. Shing graduated from the Hong Kong Polytechnic (currently known as the Hong Kong Polytechnic University) and obtained a Higher Diploma in Accountancy and was awarded of 2016/2017 Honorary University Fellow of the Hong Kong Polytechnic University. Ms. Shing has sat on a number of the HKSAR statutory committees, including, a council member of the Hong Kong Polytechnic University; and a council member and Treasurer of the HKAPA; a member of the Citizens Advisory Committee on Community Relations and Corruption Prevention Advisory Committee of the Independent Commission Against Corruption; a member of the Antiquities Advisory Board and Advisory Committee of Revitalization of Historic Buildings, and a member of the Hospital Authority. In 2006, Ms. Shing was named as one of the China’s National Hundred Outstanding Women Entrepreneurs by China Association of Women Entrepreneurs (中國女企業家協會). She also received the Outstanding Alumni Award of Hong Kong Polytechnic University in 2007. Ms. Shing has been consecutively named from 2001 to 2015 in International Tax Review as one of the World’s Leading Tax Advisors in Hong Kong and Mainland China. She is also a founding member and former president of the Association of Women Accountants (Hong Kong) Limited. Ms. Shing is currently an independent non-executive director of CSSC (Hong Kong) Shipping Company Limited (listed on the Stock Exchange, stock code: 3877), AEON Credit Service (Asia) Company Limited (listed on the Stock Exchange, stock code: 900), Sirnaomics Ltd. (listed on the Stock Exchange, stock code: 2257) and Analogue Holdings Limited (listed on the Stock Exchange, stock code: 1977) and an independent director of China Merchants Energy Shipping Co., Ltd. (listed on Shanghai Stock Exchange, stock code: 601872).

 

Kwok Kin Fun - Independent Non-executive Director


Mr. Kwok Kin Fun, BBS, JP, was appointed as an independent non-executive Director and chairman of Remuneration and Appraisal Committee, a member of Audit Committee, a member of Nomination Committee and a member of Corporate Governance Committee in June 2016. Mr. Kwok also serves as an executive committee member of Rehabilitation International and global vice chairman of Social Commission of Rehabilitation International, board member of Rehabilitation International Foundation, vice chairman of Asia and Pacific Disability Forum, a vice chairman of The Hong Kong Joint Council for Persons with Disabilities, a vice chairman of The Hong Kong Society for Rehabilitation, a council member of Fu Hong Society, a member of Hospital Authority Central Institutional Review Board (1 April 2021 to 31 March 2024), a member of Voting Members Committee of Riding For the Disabled Association, the chairman of Accessible IT Development Association Limited, a professional committee consultant to the Disabled Research and Professional Committee of the China Association of Rehabilitation of Disabled Persons (March 2019–March 2023), a professional consultant to the Professional Committee of Shenzhen Smart Assistive Tech Association, and an off-campus co-operative instructor to PHD students in the field of athletic rehabilitation in the Sports Institute of Soochow University (2019–2022). Mr. Kwok has over 30 years of experience in disability research and medical research ethics. He successively served as a senior lecturer, a principal lecturer, and an associate professor of the City University of Hong Kong from 1985 to 2009, and after retirement served as full-time and part-time senior research fellow. Mr. Kwok was appointed as a Justice of the Peace by the government of Hong Kong in 1997 and received the Bronze Bauhinia Star awarded by the government of Hong Kong SAR in 2005, “Kazuo Itoga” Memorial Prize awarded by the government of Shiga Prefecture, Japan in 2006, and the Promoter title of “Asian and Pacific Decade of Persons with Disabilities, 2013– 2022” awarded by United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP) in 2012. Mr. Kwok holds a bachelor’s degree in social science from the University of Hong Kong, a master’s degree in social work from the Chinese University of Hong Kong, and a Ph.D. degree in philosophy from the University of Nottingham, the United Kingdom.

 

Fu Tingmei - Independent Non-executive Director


Mr. Fu Tingmei, was appointed as an independent non-executive Director and Chairman of Corporate Governance Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Audit Committee in June 2016. Mr. Fu has over 20 years of experience in investment, finance, law and business management. Mr. Fu currently serves as an independent non-executive director of China Resources Medical Holdings Company Limited (stock code: 1515), Guotai Junan International Holdings Limited, a company listed on the Stock Exchange (stock code: 1788), COFCO Joycome Foods Limited (formerly known as “COFCO Meat Holdings Limited”), a company listed on the Stock Exchange (stock code: 1610) and China Zheshang Bank Co., Ltd. (a company listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 2016) and the Shanghai Stock Exchange(stock code: 601916). Mr. Fu was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017, an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019 and an independent nonexecutive director of Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) from May 2016 to March 2023. Mr. Fu holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.

 

Zhang Kejian - Independent Non-executive Director


Mr. Zhang Kejian, was appointed as an independent non-executive Director and a member of Audit Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Corporate Governance Committee in June 2016. Mr. Zhang also serves as an independent director of Zhejiang Hisoar Pharmaceutical Co., Ltd. (浙江海翔药业股份有限公司) (a company listed on Shenzhen Stock Exchange, stock code: 002099), a non-independent director of 博济医药科技股份有限公司 Boji Medical Technology Co., Ltd. (formerly known as: Guangzhou Boji Medical Biotechnological Co., Ltd. (广州博济医药生物技术股份有限公司)) (a company listed on Shenzhen Stock Exchange GEM, stock code: 300404), an independent director of Liaoning Chengda Biotechnology Co., Ltd. (辽宁成大生物股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688739) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals. Mr. Zhang has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane from February 2016 to June 2018, an independent director of Yifan Pharmaceutical Co., Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002019) from October 2014 to November 2020 and an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd (a company listed on Shanghai Stock Exchange, stock code: 603998) from October 2018 to January 2021. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences (中国医学科学院药物研究所), and successively served as a deputy director of Pharmaceutical Evaluation Center (药品审评中心) and a deputy director of Medical Device Evaluation Center (医疗器械技术审评中心) under the State Food and Drug Administration of the PRC (国家食品药品监督管理局). Mr. Zhang received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.

Back to Top